

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Contents lists available at ScienceDirect



International Journal of Infectious Diseases



journal homepage: www.elsevier.com/locate/ijid

Symptoms Experienced at the Acute Phase of SARS-CoV-2 Infection as Risk Factor of Long-term Post-COVID Symptoms: The LONG-COVID-EXP-CM Multicenter Study



César Fernández-de-las-Peñas^{1,*}, Oscar J. Pellicer-Valero², Esperanza Navarro-Pardo³, Domingo Palacios-Ceña¹, Lidiane L. Florencio¹, Carlos Guijarro^{4,5}, José D. Martín-Guerrero²

¹ Department of Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation, Universidad Rey Juan Carlos (URJC), Madrid. Spain;

² Intelligent Data Analysis Laboratory, Department of Electronic Engineering, ETSE (Engineering School), Universitat de València (UV), Valencia, Spain;

³ Department of Developmental and Educational Psychology, Universitat de València (UV), València, Spain;

⁴ Department of Medicine, Universidad Rey Juan Carlos (URJC), Madrid. Spain

⁵ Department of Internal Medicine, Hospital Universitario Fundación Alcorcón, Madrid, Spain.

ARTICLE INFO

Article history: Received 4 July 2021 Revised 2 January 2022 Accepted 4 January 2022

Keywords: COVID-19 persistent symptoms risk factors acute phase

ABSTRACT

Objective: This multicenter study investigated clinical risk factors associated with the number of long-term symptoms after COVID.

Methods: Clinical features, symptoms at hospital admission, hospitalization data, and the number of symptoms after COVID was systematically assessed for patients who recovered from COVID-19 in 4 hospitals in Madrid (Spain) from February 20 to May 31, 2020.

Results: Overall, 1,969 patients (46.5% women, age: 61, SD: 16 years) were randomly assessed 8.4 months (SD 1.5) after hospital discharge. Female gender (odds ratio [OR] 1.82, 95% confidence interval [CI] 1.57-2.10), number of morbidities (OR 1.182, 95% CI 1.08-1.29), number of symptoms at hospital admission (OR 1.309, 95% CI 1.15-1.49) and days at the hospital (OR 1.01, 95% CI 1.007-1.017) were associated (all, p < 0.001) with more long-term symptoms after COVID. Further, vomiting (OR 1.78, 95% CI 1.26-2.52), throat pain (OR 1.36, 95% CI 1.02-1.81), diarrhea (OR 1.51, 95% CI 1.25-1.82), dyspnea (OR 1.20, 95% CI 1.28-1.75) as symptoms at hospital admission were also associated (all, p < 0.01) with a higher number of symptoms after COVID.

Conclusion: This multicenter study found that a higher number of symptoms at hospital admission were the most relevant risk factor for developing more symptoms after COVID, supporting the assumption that a higher symptom load at the acute phase is associated with a greater likelihood of long-term symptoms after COVID.

© 2022 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

Introduction

The presence of symptoms after COVID range from 35% to 60% (Fernández-de-las-Peñas et al., 2021). Identification of risk factors is needed for early monitoring of individuals at a high risk of developing symptoms after COVID, yet present data are still limited (lqbal et al., 2021). Potential identified risk factors described in former literature include female gender, more onset symptoms (higher symptom load), older age, longer hospital stay, and a

* Corresponding author: César Fernández-de-las-Peñas, Facultad de Ciencias de la Salud, Universidad Rey Juan Carlos, Avenida de Atenas s/n 28922 Alcorcón, Madrid, Spain, Telephone number: + 34 91 488 88 84, fax number: +34 91 488 89 57.

E-mail address: cesar.fernandez@urjc.es (C. Fernández-de-las-Peñas).

higher number of co-morbidities (Yong et al., 2021). Nevertheless, contradictory results are also observed between studies. Further, most of the studies included samples of <300 patients and were recruited from single centers (lqbal et al., 2021). A study including a large number of COVID-19 patients reported a prevalence of long-term sick leave from work of 5.8% (Jacobs et al., 2021). These authors found that female gender, older age, and co-morbid medical conditions were significantly associated with long-term sick leave (Jacobs et al., 2021). We describe here a large multicenter study investigating clinical risk factors related to hospitalization associated with the number of long-term symptoms after COVID in a large population sample.

https://doi.org/10.1016/j.ijid.2022.01.007

^{1201-9712/© 2022} The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)




Figure. Positive associations between the number of long-term symptoms after COVID with the number of pre-existing co-morbidities (left) or the number of COVID-19 onset symptoms at hospital admission

Methods

The LONG-COVID-EXP-CM is a multicenter cohort study including individuals hospitalized with a diagnosis of SARS-CoV-2 during the first wave of the pandemic in 5 public hospitals in Madrid (Spain). A sample of 400 individuals from each hospital was randomly selected. All Local Ethics Committees approved the study (HCSC20/495E, HSO25112020, HUFA 20/126, HUIL/092-20, HUF/EC1517). Informed consent was obtained from all participants. Participants were scheduled for a telephone interview conducted by experienced healthcare professionals, were systematically asked about a list of symptoms after COVID (multiple symptoms could be selected by the same patient), but were free to report any additional symptom that they experienced at the time of the study. Clinical data (i.e., gender, age, height, weight, comorbidities), COVID-19 symptoms at hospital admission, and hospitalization (i.e., days at hospital, intensive care unit admission) data were collected from medical records.

Mean and SD or percentages were calculated. Missing values were imputed using median imputation. Multivariate logistic regressions were conducted to analyze associations between clinical and hospitalization variables with the number of symptoms after COVID (dependent variable) using Python library statsmodels 0.11.1. Adjusted odds ratio (OR) and confidence intervals (95% CI) were calculated.

Results

From 2,000 patients randomly selected and invited to participate, a total of 1,969 (46.5% women, age: 61, SD: 16 years) participated. The most prevalent symptoms at hospital admission were fever (74.6%), dyspnea (31.5%), and myalgia (30.7%). Almost 57.5% of the individuals (n = 1,133) reported at least one co-morbidity. Participants were assessed 8.4 months (SD 1.5) after hospital discharge. Almost 1 out of 5 patients (n = 367, 18.7%) were free of symptoms after COVID, whereas 34.4% (n = 679) experienced \geq 3 symptoms after COVID. The mean number of symptoms after COVID was 1.9 (SD 1.4). The most frequent long-term symptoms after COVID included fatigue (61.3%) and dyspnea (23.3%).

Female gender (OR 1.82, 95% CI 1.57-2.10), number of COVID-19 symptoms at hospital admission (OR 1.309, 95% CI 1.15-1.49), number of pre-existing medical co-morbidities (OR 1.182, 95% CI 1.08-1.29), and days at hospital (OR 1.01, 95% CI 1.007-1.017) were independently associated (all, p <0.001) with more long-term symptoms after COVID: the higher the number of COVID-19 onset symptoms or the higher the number of co-morbidities, the higher the number of symptoms after COVID (**Figure**). No specific co-morbidity (e.g., obesity, hypertension) was associated with a greater number of symptoms after COVID. Some specific symptoms at the acute phase were also independently associated (all, p < 0.01) with a higher number of long-term symptoms after COVID (**Table**): vomiting (OR 1.78, 95% CI 1.26-2.52), throat pain (OR 1.36, 95% CI 1.02-1.81), diarrhea (OR 1.51, 95% CI 1.25-1.82), dyspnea (OR 1.20, 95% CI 1.01-1.41), or headache (OR 1.50, 95% CI 1.28-1.75).

Discussion

This multicenter study found that female gender, a greater number of symptoms at hospital admission, a greater number of pre-existing medical co-morbidities, and a longer stay at the hospital were risk factors for developing more long-term symptoms after COVID. In all these risk factors, it seems that a higher number of symptoms at hospital admission was the most relevant for developing more symptoms after COVID. The presence of some specific symptoms at hospital admission such as vomiting, throat pain, diarrhea, dyspnea, or headache was also associated with long-term symptoms after COVID. No specific medical co-morbidity was associated with a greater number of long-term symptoms after COVID. Our data support previous assumptions that a higher symptom load at the acute phase is associated with a greater likelihood of long-term symptoms after COVID (Iqbal et al., 2021; Yong, 2021). The role of previous medical co-morbidities as a risk factor for symptoms after COVID needs further studies. We also observed that the female gender was a potential risk factor for symptoms after COVID, in agreement with previous assumptions (Iqbal et al., 2021). Specific studies investigating gender differences are needed.

Our results should be considered according to some potential weaknesses. First of all, only hospitalized patients participated. Second, we did not collect objective data on COVID-19 disease. Third, the cross-sectional design did not permit the determination of cause-and-effect associations.

Author Contributions

Dr Fernández-de-las-Peñas and Dr. Palacios-Ceña had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: All authors. Drafting of the manuscript: All authors. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: Dr. Pellicer-Valero. Supervision: Dr. Martín-Guerrero

Declaration of interests

No conflict of interest is declared by any of the authors

Table Clinical/Hospitalization Data and Symptoms after COVID (n = 1,969)

(46.58) (46.58) Height, mean (SD), kg. 75 (15) Height, mean (SD), kg. 165 (15.) Main Syngthoms at hospital admission, n (%) 149 (74.68) Fever 1.469 (74.68) Dyspnea. 602 (31.58) Mydigia 604 (30.78) Cough 604 (30.78) Headache 332 (16.93) Diarthea 310 (10.78) Anosmia 167 (8.58) Throat Pain 167 (8.58) Noner 66 (33.59) One 715 (56.33) Nomer of medical co-morbidities, n (%) 816 (42.53) None 715 (56.33) One 716 (64.53) One 716 (56.33) One 716 (56.33) One 716 (56.33) One 716 (56.34) Oneido (Comorbid		
(46.3%) (46.3%) Weight, mean (SD), kg. 75 (15) Height, mean (SD), kg. (76) Height, mean (SD), kg. (76) Fever (46) (74.8%) Dyspoea (62) (31.3%) Oxyappea (62) (31.3%) Myaigia 604 (30.7%) Cough 549 (27.9%) Headache 210 (10.7%) Diarthea 210 (10.7%) Anosmia 102 (5.2%) Ageusia 66 (33.5%) Number of medical co-morbidities, n (%) 86 (42.5%) None 281 (14.2%) None 281 (14.2%) None 281 (14.2%) One 71 (36.3%) Jawa 281 (14.2%) Jawa 281 (14.2%) Jawa 281 (14.2%) Jawa 284 (11.9%) Stroke 32 (15.3%) Cardiovascular Disease 23 (15.3%) Jawa 234 (11.9%) Stroke 31 (12.4%) Medical Co-morbidities 32 (15.3%) Hyp	Age, mean (SD), years	61 (16)
Weight, mean (SD), kg.'75 (15)Height, mean (SD), kg.1469 (74.68)Pever1469 (74.68)Dysponea620 (31.53)Gough640 (27.36)Cough549 (27.35)Cough549 (27.35)Janrha107 (16.35)Janrha610 (35.30)Janrha610 (35.30)Jorna610 (35.30)Jorna836 (42.53)Jorna76 (35.30)Jorna121 (14.30)Jorna121 (14.30)Jorna121 (14.30)Jorna121 (14.30)Jorna121 (14.30)Jorna126 (25.30)Jorna126 (25.30)Jorna130 (14.30)Jorna130 (65.37) (15.30)Jorna130 (65.37) (15.30)Jorna130 (65.37) (15.30)Jorna130 (65.37) (15.30)Jorna126 (25.30)Jorna130 (25.30)Jorna130 (25.30)Jorna130 (25.30)Jorna130 (25.30)Jorna130 (25.30)Jorna130 (25.30)	Gender, male/female (%)	1,054 (53.5%) / 915
Height mean (SD) cm.165 (16.5)Wain Symptons at hospital admission, n (%)1469 (74.68)Fever1469 (74.68)Pever1469 (74.68)Dispance604 (30.73)Mydigia604 (30.73)Cough604 (30.73)Headache210 (10.73)Jarnhea101 (25.23)Anosmia167 (8.58)Throat Pain66 (33.58)Vomiting66 (33.58)Vomiting66 (33.58)Number of medical co-morbidities, n (%)816 (42.58)Number of medical co-morbidities, n (%)816 (42.58)Number of medical co-morbidities, n (%)816 (42.58)Number of medical co-morbidities, n (%)816 (42.58)One816 (42.58)		(46.5%)
Height mean (SD) cm.165 (16.5)Main Symptoms at hospital admission, n (%)14.69 (74.68)Ever1.469 (74.68)Sysposa604 (30.73)Mydigia604 (30.73)Cough402 (27.93)Headache322 (15.93)Diarthea101 (0.73)Anosmia102 (5.83)Anosmia66 (33.53)Jonathea66 (33.53)Vomiting66 (33.53)Vomiting66 (33.53)Number of medical co-morbidities, n (%)81 (42.53)Number of medical co-morbidities, n (%)81 (42.53)Number of medical co-morbidities, n (%)81 (42.53)Number of medical co-morbidities, n (%)81 (42.53)One81 (42.53)Jone one81 (42.51)Jone one81 (42.51)Jone one81 (42.51)Jone one81 (42.51)Jone one one one of the second secon	Neight, mean (SD), kg.	75 (15)
Nain symptoms at hospital admission, n (%) 1.469 (74.63) Pever 1.469 (74.63) Dyspnoea 620 (31.53) Myalgia 620 (31.53) Ough 540 (27.93) Headache 532 (15.83) Diarhea 210 (10.73) Anosmia 102 (52.8) Ageusia 66 (33.55) Vomiting 856 (42.53) Number of medical co-morbidities, n (%) 856 (42.53) Number of medical co-morbidities, n (%) 816 (42.53) Yow 281 (14.23) 3 or more 816 (42.53) Two 281 (14.23) 3 or more 137 (73) Medical co-morbidities 137 (73) Hypertension 126 (6.44) Obesity 236 (12.03) Cardiovascular Disease 37 (13.93) Stroke 31 (16.8) Other (Concr, Kidney Disease) 31 (16.8) Other (Concr, Kidney Disease) 31 (16.8) Stroke 31 (10.2) (34.8) Dong-term symptoms after COVID, n (%) 326 (12.8) None </td <td></td> <td>165 (16.5)</td>		165 (16.5)
Fever 1.499 (74.63) Dyspnes 602 (31.53) Myaja 604 (30.73) Gough 644 (20.73) Headache 332 (16.93) Headache 332 (16.93) Diarthea 107 (10.73) Anosmia 167 (8.55) Thoat Pain 66 (33.53) Yomiting 66 (33.53) Number of medical co-morbidities, n (%) 715 (36.33) None 715 (36.33) One 715 (36.33) None 715 (36.33) One 716 (46.82) One 715 (36.33) One 715 (36.33) Ora oracle Co-morbidities 137 (73) Hypertension 134 (42.13) Diabetes 514 (26.13) Diabetes 71 (36.33) Stroke 71 (36.33) One 71 (36.33)		
pyspnoea620 (31.3) (20.4)620 (43.0.3)Walgia620 (43.0.3)549 (27.93)Caugh549 (27.93)549 (27.93)Headache210 (10.73)Anosmia101 (5.23)Anosmia102 (5.23)66 (33.53)Vomiting65 (33.53)Yomiting55 (2.83)55 (2.83)55 (2.83)None886 (42.53)715 (36.33)715 (36.33)Yom886 (42.53)715 (36.33)716 (36.33)Yom886 (42.53)715 (36.33)717 (36.33)Yom816 (42.53)715 (36.33)716 (36.33)Yom816 (42.53)716 (36.33)716 (36.33)Rentartological Disease816 (42.13)716 (36.33)Yom82 (11.83)717 (38.33)716 (36.33)Yom82 (11.83)717 (38.33)716 (36.33)None91 (11.83)71 (38.3)716 (36.33)None91 (11.83)71 (38.3)716 (36.33)Yom92 (91.93)71 (91.93)716 (36.33)None91 (11.93)71 (38.3)716 (36.33)None91 (91.53)91 (91.53)716 (91.53)Yom91 (91.93)91 (9		1 469 (74 6%)
Myalgia604 (20.7a)Cough549 (27.9a)Headache322 (16.93)Diarthea167 (8.55)Nuoat Pain167 (8.55)Nuoat Pain66 (33.50)Symme66 (33.50)Number of medical co-morbidities, n (%)86 (33.50)Number of medical co-morbidities, n (%)86 (42.53, 80)Nune715 (86.33, 90)None715 (86.33)One715 (86.33)One715 (86.33)One715 (86.33)One716 (86.33) <tr< td=""><td></td><td></td></tr<>		
Cough549 (27.98)Darhea312 (15.98)Darhea210 (10.78)Anosmia107 (8.58)Throat Pain107 (8.57)Reutsia66 (3.55)Somiting66 (3.55)None66 (3.57)One715 (36.38)One715 (36.38)Jorne281 (14.22)Jorne11.2 (14.22)Jorne11.2 (14.22)Jorne11.2 (14.22)Jorne11.2 (14.22)Jorne12.6 (14.22)Cardiovascular Disease23.4 (11.08)Jorne12.6 (14.22)Jorne12.6 (14.22)Jorne12.6 (16.42)Jorne13.2 (15.63)Stroke32.2 (15.93)Stroke33.2 (15.93)None13.0 (11.63)Vers/No. n. (3.)13.0 (16.8)None31.0 (16.8)Jorne13.0 (16.8)Jorne13.0 (16.8)Jorne13.0 (16.8)None13.0 (16.8)None13.0 (16.8)Jorne13.0 (16.8)Jorne13.0 (16.8)Jorne13.0 (16.8)Jorne13.0 (16.8)Jorne13.0 (16.8)Jorne13.0 (16.8)Jo		
Headache332 (16.30, 100, 100, 100, 100, 100, 100, 100, 1		
Diarhea210 (10.7%) 107 (85.7%)Anosmia107 (85.7%) 107 (85.7%)Anosmia107 (85.7%) 107 (85.7%)Ageusia66 (33.5%) 107 (85.7%)Numer of medical co-morbidities, n (%)886 (42.5%)Numer of medical co-morbidities, n (%)886 (42.5%)Numer of medical co-morbidities, n (%)886 (42.5%)Numer of medical co-morbidities, n (%)886 (42.5%)One886 (42.5%)One281 (14.2%)Jo more281 (14.2%)Medical co-morbidities126 (64.3%)Hypertension126 (64.5%)Ohabetes236 (12.0%)Cardiovascular Disease234 (11.9%)Asma126 (64.5%)Oheroic Obstructive Pulmonary Disease71 (39.3%)Stroke31 (1.6%)Oher (Cancer, Kidney Disease)31 (1.6%)Oher (Cancer, Kidney Disease)31 (1.6%)Oher (Cancer, Kidney Disease)31 (1.6%)Stroke30 (65.8%) / 13)Numer of long-term symptoms after COVID, n (%)130 (65.8%) / 133None367 (13.7%)Ong1206 (61.3%)Dyspneea1206 (61.3%)Jyspneea1206 (61.3%)Jost Strate1206 (61.3%)<		
Anosmia167 (8.58)Argensia66 (33.58)Agensia66 (33.58)Number of medical co-morbidities, n (%)88 (42.58)Number of medical co-morbidities, n (%)88 (42.58)Nume88 (42.58)One88 (42.58)One137 (75.338)Two281 (14.28)J or more137 (75.338)Medical co-morbidities137 (75.338)Hypertension514 (26.18)Diabetes236 (12.08)Cardiovascular Disease77 (3.98)Cardiovascular Disease77 (3.98)Stroke73 (26.83)Obesity88 (4.53)Chronic Obstructive Pulmonary Disease77 (3.98)Stroke31 (1.68)Obesity38 (2.08)Rheumatological Disease31 (1.68)Other (Cancer, Kidney Disease)32 (16.98)Stay at the hospital, mean (SD), days130 (6.68.) / 1.1Number of long-term symptoms after COVID, n (%)36 (2.18)Two36 (2.18)36 (1.8.78)One120 (6.138)36 (1.133)Dyspneea140 (7.18)Astales236 (1.208)Strik Ashes36 (2.108)Strik Ashes36 (2.108)Oucular/Vision Disorders140 (7.18)Astales38 (4.253)Orother Supponea38 (4.253)Outular Construction Disorders38 (4.253)Outular Construction Disorders38 (4.253)Outular Construction Disorders38 (4.253)Outular Vision Disorders38 (4.253)O		
Throat Pain102 (5.23) 66 (3.55)Number of medical co-morbidities, n (%)836 (42.58)Number of medical co-morbidities, n (%)836 (42.58)Nume836 (42.58)One836 (42.58)One836 (42.58)One836 (42.58)Orne836 (42.58)Jorne836 (42.58)Jorne837 (78)Medical co-morbidities837 (78)Hypertension514 (26.18)Diabetes236 (12.08)Cardiovascular Disease236 (12.08)Aama126 (64.48)Obesity88 (45.89)Chronic Obstructive Pulmonary Disease77 (33.88)Stroke88 (20.88)Rheumatological Disease312 (16.89)Stay at the hospital, mean (SD), days332 (16.98)Intensive Care, Kidney Disease)313 (17.41)Ves/No. (%)10 (6.58) (13.91)None367 (18.78)One367 (18.78)One368 (28.28)Orne368 (28.28)Orne368 (28.28)Orne368 (28.28)Orne368 (28.28)Orne368 (28.28)Orne368 (28.28)Orne368 (28.		
Agensia66 (33,5%)Vomiting55 (2.8%)Number of medical co-morbidities, n (%)836 (42,5%)Nume936 (42,5%)One936 (42,5%)One936 (42,5%)One936 (42,5%)Two936 (42,5%)S or more137 (78)Medical co-morbidities137 (78)Hypertension134 (26,1%)Cardiovascular Disease236 (11,9%)Cardiovascular Disease236 (12,0%)Stroke88 (45%)Chronic Obstructive Pulmonary Disease131 (16%)Stroke38 (20%)Rheumatological Disease311 (16%)Other Clarner, Kidney Disease)321 (16,9%)Stroke Care Unit (ICU) admission130 (65%) / 13Ves/No, n (%)307 (18,7%)Nome307 (18,7%)Nome307 (18,7%)Nome307 (18,7%)Nome307 (18,7%)Cong-Term symptoms after COVID, n (%)1206 (61,3%)Two336 (20,3%)Strik Rashes36 (23,3%)Josponea410 (71,3%)Josponea30 (43%)Coular Vision Disorders30 (43%)Curantific Disorders30 (23,3%)Coular Vision Disorders<	Anosmia	167 (8.5%)
Vomitring 55 (2.82) Number of medical co-morbidities, n (%) 836 (42.53) None 836 (42.53) One 281 (14.22) Sor more 281 (14.22) 3 or more 281 (14.22) dedical co-morbidities 281 (14.22) Hypertension 236 (12.08) Cardiovascular Disease 236 (12.08) Cardiovascular Disease 234 (11.98) Asma 236 (6.43) Obesity 281 (14.22) Stroke 82 (2.08) Rheumatological Disease 31 (1.63) Other (Cancer, Kidney Disease) 32 (16.98) Stroke 332 (16.98) Number of long-term symptoms after COVID, n (%) 937 None 67 (18.78) One 36 (2.13) None 679 (34.43) Jospena 459 (2.33) Jospena 459 (2.33) Loss memory 459 (2.33) Stroke 140 (7.18) Stroke 140 (7.18) Stroke 140 (7.18) Strok	Throat Pain	102 (5.2%)
Number of medical co-morbidities, n (%) 86 (42.5%) None 86 (42.5%) None 715 (36.3%) Yavo 281 (14.2%) 3 or more 137 (78) Medical co-morbidities 137 (78) Hypertension 514 (26.1%) Diabetes 236 (12.0%) Cardiovascular Disease 234 (11.9%) Asma 126 (6.4%) Obesity 88 (4.5%) Chronic Obstructive Pulmonary Disease 31 (1.6%) Other (Cancer, Kidney Disease) 311 (1.6%) Strade 312 (16.9%) Other (Cancer, Kidney Disease) 323 (16.9%) Strad at the hospital, mean (5D), days 113 (1.4%) Intensive Care Unit (ICU) admission 112 Ves/No. n (%) 30 (6.6%) / 1.1 Number of long-term symptoms after COVID, n (%) 30 (6.6%) / 1.1 Number of long-term symptoms after COVID, n (%) 120 (6.1.3%) None 1206 (6.1.3%) Dyspnoea 459 (23.3%) Long Term symptoms after COVID, n (%) 120 (6.1.3%) None 120 (6.1.3%)	Ageusia	66 (33.5%)
None 336 (42.5x) (75 (36.33) Two 281 (14.28) 3 or more 137 (73) Medical co-morbidities 137 (73) Hypertension 514 (26.18) Diabetes 236 (12.08) Cardiovascular Disease 234 (11.98) Asma 236 (6.28) Obesity 88 (4.53) Chronic Obstructive Pulmonary Disease 77 (3.98) Stroke 36 (2.08) Rheumatological Disease 32 (16.98) Other (Cancer, Kidney Disease) 32 (16.98) Stroke 32 (16.98) Intensive Care Unit (1CU) admission 32 (16.98) YeyNo, n (%) 130 (66.67) (1.3) Number of long-term symptoms after COVID, n (%) 36 (2.218) None 67 (18.78) None 36 (2.18) Jo ar more 120 (61.38) Syspneca 459 (23.33) Loss memory 346 (21.13) Stin Rashes 189 (95.83) Loss memory 36 (2.12) Stin Rashes 140 (7.13) Stin Rashes	/omiting	55 (2.8%)
One115 (58.30) 281 (14.28)Two281 (14.28)3 or more131 (28.18)Medical co-morbidities141 (28.18)Uppertension141 (26.18)Cardiovascular Disease236 (12.08)Cardiovascular Disease236 (12.08)Asma126 (6.48)Obesity88 (4.53)Chronic Obstructive Pulmonary Disease77 (3.98)Stroke88 (24.58)Chronic Obstructive Pulmonary Disease31 (1.68)Stroke81 (1.68)Rheumatological Disease32 (16.98)Stray at the hospital, mean (SD), days130 (6.63) / 1.1Other Cancer, Kidney Disease)367 (18.78)Stray at the hospital, mean (SD), days130 (6.63) / 1.1Intensive Care Unit (ICU) admission100 (6.63) / 1.1Vember of long-term symptoms after COVID, n (%)367 (18.78)None367 (18.78)One367 (18.78)Cong-term symptoms after COVID, n (%)369 (23.38)Tog-ferm symptoms after COVID, n (%)369 (23.38)Log-term symptoms after COVID, n (%)12.06 (61.38)Strin Rashes12.06 (61.38)Dyspnoea140 (7.18)Gastrointerstinal Disorders130 (6.59)Anosmia36 (2.78)Triture Asile39 (25.80)Vitterion Disorders31 (27.80)Arbeat49 (2.58)Voiter Poblems90 (25.81)Diarbea90 (25.81)Diarbea90 (25.81)Diarbea90 (25.81)Diarbea90 (25.81)V	Number of medical co-morbidities, n (%)	
One115 (58.30) 281 (14.28)Two281 (14.28)3 or more131 (28.18)Medical co-morbidities141 (28.18)Uppertension141 (26.18)Cardiovascular Disease236 (12.08)Cardiovascular Disease236 (12.08)Asma126 (6.48)Obesity88 (4.53)Chronic Obstructive Pulmonary Disease77 (3.98)Stroke88 (24.58)Chronic Obstructive Pulmonary Disease31 (1.68)Stroke81 (1.68)Rheumatological Disease32 (16.98)Stray at the hospital, mean (SD), days130 (6.63) / 1.1Other Cancer, Kidney Disease)367 (18.78)Stray at the hospital, mean (SD), days130 (6.63) / 1.1Intensive Care Unit (ICU) admission100 (6.63) / 1.1Vember of long-term symptoms after COVID, n (%)367 (18.78)None367 (18.78)One367 (18.78)Cong-term symptoms after COVID, n (%)369 (23.38)Tog-ferm symptoms after COVID, n (%)369 (23.38)Log-term symptoms after COVID, n (%)12.06 (61.38)Strin Rashes12.06 (61.38)Dyspnoea140 (7.18)Gastrointerstinal Disorders130 (6.59)Anosmia36 (2.78)Triture Asile39 (25.80)Vitterion Disorders31 (27.80)Arbeat49 (2.58)Voiter Poblems90 (25.81)Diarbea90 (25.81)Diarbea90 (25.81)Diarbea90 (25.81)Diarbea90 (25.81)V	None	836 (42.5%)
Two 281 (1422) 3 or more 137 (78) Medical co-morbidities 137 (78) Hypertension 514 (26.18) Diabetes 236 (12.08) Cardiovascular Disease 234 (11.98) Asma 236 (6.48) Obesity 88 (4.58) Chronic Obstructive Pulmonary Disease 77 (3.98) Stroke 88 (2.08) Rheumatological Disease 31 (1.68) Other (Cancer, Kidney Disease) 312 (16.98) Stay at the hospital, mean (SD), days 113 (11.4) Intensive Care Unit (ICU) admission 130 (6.68.) / 1.3 Yes/No. n (%) 130 (6.68.) / 1.4 None 367 (18.78) One 436 (2.21.8) Yoo 436 (2.21.8) Yoo 436 (2.21.8) Dyspnoea 459 (3.33.0) Loss memory 459 (23.33.0) Stin Rashes 236 (10.20.8) Starin fog 140 (7.13.2) Palpitations 140 (7.13.2) Palpitations 140 (7.13.2) Palpitations	Die	
3 or more 137 (7%) Medical co-morbidities 144 (26.1%) Pupertension 236 (12.0%) Cardiovascular Disease 236 (12.0%) Asma 126 (6.4%) Obesity 88 (4.5%) Chronic Obstructive Pulmonary Disease 77 (3.9%) Stroke 88 (2.0%) Rheumatological Disease 77 (3.9%) Stroke 38 (2.0%) Rheumatological Disease 73 (3.9%) Stroke 38 (2.0%) Stroke (Cancer, Kidney Disease) 322 (16.9%) Stay at the hospital, mean (SD), days 113 (1.6%) Intensive Care Unit (ICU) admission (93.4%) Yes/No, n (%) (93.4%) None 367 (18.7%) One 436 (22.1%) None 1206 (61.3%) Jysponea 458 (24.8%) Jor more 1206 (61.3%) Logs ferm symptoms after COVID, n (%) 1206 (61.3%) Stin Rashes 236 (12.0%) Starity 1206 (61.3%) Dysponea 1206 (61.3%) Starity		
Medical co-morbidities 514 (26.13, 1) Hypertension 514 (26.13, 2) Diabetes 236 (12.08) Cardiovascular Disease 234 (11.98) Asma 234 (11.98) Obesity 88 (4.58) Chronic Obstructive Pulmonary Disease 77 (3.93, 13) Stroke 77 (3.93, 13) Chronic Obstructive Pulmonary Disease 77 (3.93, 13) Stroke 38 (2.08) Rheumatological Disease 312 (16.93) Stay at the hospital, mean (SD), days 11.3 (11.4) Intensive Care Unit (ICU) admission 130 (6.62, 1/ 1, 10.8) Ves/No. n (%) 130 (6.62, 1/ 1, 10.8) Number of long-term symptoms after COVID, n (%) 130 (6.62, 1/ 1, 10.8) None 367 (18.78) One 367 (18.78) One 367 (18.78) Stay at the cospital, mean (SD, days 130 (6.62, 1/ 1, 10.8) None 367 (18.78) One 367 (18.78) One 367 (18.78) Stay at the cospital, mean (SD, days 130 (6.78, 17) Number of long-term symptoms after COVID,		
Hypertension514 (26.1%)Diabetes236 (12.0%)Cardiovascular Disease234 (11.9%)Asma126 (6.4%)Obesity88 (4.5%)Chronic Obstructive Pulmonary Disease77 (3.9%)Stroke88 (2.0%)Rheumatological Disease31 (1.6%)Other (Cancer, Kidney Disease)322 (16.9%)Stay at the hospital, mean (SD), days113 (11.4)Intensive Care Unit (ICU) admission130 (6.6%) / 11,Yes/No, n (%)130 (6.6%) / 12,None367 (18.7%)One367 (18.7%)One367 (18.7%)One367 (18.7%)One367 (18.7%)Dyspnosa after COVID, n (%)120 (6.13%)Two367 (18.7%)One367 (18.7%)One367 (18.7%)One367 (18.7%)One367 (18.7%)One367 (18.7%)Dyspnosa140 (7.1%)Fatigue1206 (61.3%)Dyspnosa348 (24.8%)Loss memory348 (24.8%)Stin Rashes349 (17.3%)Brain fog140 (7.1%)Attention Disorders140 (7.1%)Attention Disorders36 (27.8%)Anosmia30 (27.8%)Attention Disorders39 (27.8%)Ovice Problems39 (28.9%)Cortoret Symptom at Hospital Admission39 (28.9%)NumberInfo-sterns39 (27.8%)Dyspnosa (n=620)21.5%)31.1%)No Dyspnose (n=620)21.5%)31.5%) <td></td> <td>137 (7%)</td>		137 (7%)
Date236 (12.02)Cardiovascular Disease234 (11.93)Asma126 (6.4%)Obesiry88 (4.5%)Chronic Obstructive Pulmonary Disease77 (398)Stroke38 (2.0%)Rheumatological Disease312 (1.6%)Other (Cancer, Kidney Disease)312 (1.6%)Stay at the hospital, mean (SD), days11.3 (11.4)Intensive Care Unit (ICU) admission130 (6.6%) / 1.1Werst of long-term symptoms after COVID, n (%)130 (6.6%) / 1.1None0367 (18.7%)One367 (18.7%)One367 (18.7%)One486 (24.8%)3 or more486 (24.8%)Jorgener symptoms after COVID, n (%)1206 (61.3%)Tatigue1.206 (61.3%)Dyspneea459 (23.3%)Loss memory341 (17.3%)Skin Rashes236 (12.0%)Brain fog140 (7.1%)Attention Disorders140 (7.1%)Gastrointestinal Disorders140 (7.1%)Jourders140 (7.1%)Aussina50 (25.5%)Diartheat50 (25.5%) </td <td></td> <td>514 (26 1%)</td>		514 (26 1%)
Cardiovascular Disease 234 (11.92) Asma 126 (6.42) Obesity 88 (4.53) Chronic Obstructive Pulmonary Disease 77 (3.93) Stroke 88 (2.08) Rheumatological Disease 31 (1.63) Other (Cancer, Kidney Disease) 322 (16.98) Stay at the hospital, mean (SD), days 11.3 (11.4) Intensive Care Unit (ICU) admission (93.66.%) / 1.1 Yes/No, n (%) (93.66.%) / 1.1 None 367 (18.7%) One 436 (22.1%) None 677 (18.7%) One 436 (22.1%) Two 436 (22.1%) Sor more 1206 (61.3%) Dyspnoea 459 (23.3%) Loss memory 341 (17.3%) Sin Rashes 130 (6.7%) Sor more 1206 (61.3%) Ocular/Vision		
Asma 126 (6.4%) Obesity 88 (4.5%) Obesity 88 (4.5%) Stroke 38 (2.0%) Stroke 31 (1.6%) Other (Cancer, Kidney Disease) 312 (1.6%) Stay at the hospital, mean (SD), days 11.3 (11.4) Intensive Care Unit (ICU) admission 130 (6.6%) / 1.4 Yes/No, n (%) 130 (6.6%) / 1.4 None 367 (18.7%) None 367 (18.7%) None 367 (18.7%) Two 366 (22.1%) Two 436 (22.1%) None 436 (22.1%) Long-Term symptoms after COVID, n (%) 1206 (61.3%) Long-Term symptoms after COVID, n (%) 1206 (61.3%) Long-Term symptoms after COVID, n (%) 1206 (61.3%) Skin Rashes 1206 (61.3%) Joss memory 341 (17.3%) Skin Rashes 236 (12.0%) Brain fog 140 (7.1%) Castiontestinal Disorders 140 (7.1%) Altention Disorders 133 (6.7%) Coular/Wision Disorders 39 (2.5%) Diarthea 50 (2.5%) Diarthea <td></td> <td></td>		
Obesity 88 (4.5%) Chronic Obstructive Pulmonary Disease 77 (3.9%) Stroke 38 (2.0%) Rheumatological Disease 31 (1.6%) Other (Cancer, Kidney Disease) 332 (16.9%) Stay at the hospital, mean (SD), days 11.3 (11.4) Intensive Care Unit (ICU) admission 130 (6.6%) / 1, (93.4%) Number of long-term symptoms after COVID, n (%) (93.4%) None 367 (18.7%) One 436 (22.1%) Yavo 488 (24.8%) 3 or more 436 (22.1%) Yavo 488 (24.8%) S or more 1206 (61.3%) Long-Term symptoms after COVID, n (%) 1206 (61.3%) Long-Term symptoms after COVID, n (%) 1206 (61.3%) Long-Term symptoms after COVID, n (%) 130 (5.6%) Long-Term symptoms after COVID, n (%) 132 (5.7%) Dyspnoea 149 (7.1%) Patigue 1206 (61.3%) Justin Bashes 313 (6.7%) Coular/Vision Disorders 133 (6.7%) Coular/Vision Disorders 133 (6.7%) Coular/Vision Disorders		
Chronic Obstructive Pulmonary Disease 77 (3.9%) Stroke 38 (2.0%) Rheumatological Disease 31 (1.6%) Other (Cancer, Kidney Disease) 322 (16.9%) Stay at the hospital, mean (SD), days 11.3 (11.4) Intensive Care Unit (ICU) admission 120 (6.6%) / 1.4 Yes/No, n (%) 130 (6.6%) / 1.4 Number of long-term symptoms after COVID, n (%) 367 (18.7%) None 367 (18.7%) One 367 (18.7%) One 488 (24.8%) 3 or more 468 (24.8%) 1 Cong-Term symptoms after COVID, n (%) 488 (24.8%) String Ear Symptoms after COVID, n (%) 1206 (61.3%) Dyspnoea 1.206 (61.3%) Dyspnoea 1.206 (61.3%) String Ear Symptoms after COVID, n (%) 1206 (61.3%) String Ear Symptoms after COVID, n (%) 1206 (61.3%) Dyspnoea 1206 (61.3%) Outer Problems 130 (6.7%) Curvid Printo Disorders 140		
Stroke 38 (2.0%) Rheumatological Disease 31 (1.6%) Other (Cancer, Kidney Disease) 332 (16.9%) Stay at the hospital, mean (SD), days 11.3 (11.4) Intensive Care Unit (ICU) admission 130 (6.6%) / 1.3 Yes/No, n (%) (93.4%) Number of long-term symptoms after COVID, n (%) (93.4%) None 367 (18.7%) One 436 (22.1%) Two 436 (22.1%) Two 436 (22.1%) Two 436 (23.3%) Jorne 679 (34.4%) Long-Term symptoms after COVID, n (%) (44.5%) Fatigue 1,206 (61.3%) Dyspnoea 459 (23.3%) Loss memory 341 (17.3%) Skin Rashees 236 (12.0%) Brain fog 140 (7.1%) Castrointestinal Disorders 133 (6.7%) Cultr/Vision Disorders 133 (6.7%) Anosmia 80 (4%) Ageusia 50 (2.55%) Diarrhea 49 (2.5%) Diarrhea 49 (2.5%) Diarrhea	Desity	88 (4.5%)
Rheumatological Disease 31 (1.6%) Other (Cancer, Kidney Disease) 332 (16.9%) Stay at the hospital, mean (SD), days 133 (16.6%) Intensive Care Unit (ICU) admission 130 (6.6%) / 11, (93.4%) Number of long-term symptoms after COVID, n (%) (93.4%) Number of long-term symptoms after COVID, n (%) 367 (18.7%) One 436 (22.1%) Two 488 (24.8%) 3 or more 679 (34.4%) Long-Term symptoms after COVID, n (%) 1206 (61.3%) Patigue 1.206 (61.3%) Joss nemory 341 (17.3%) Skin Rashes 236 (12.0%) Brain fog 439 (23.3%) Ocular/Vision Disorders 140 (7.1%) Palpitations 140 (7.1%) Coular/Vision Disorders 133 (6.7%) Ocular/Vision Disorders 36 (2.5%) Diarthea 49 (2.5%) Voice Problems 39 (2%) COVID-19 Onset Symptom at Hospital Admission Sin (2.5%) Number Long-term Symptomes after COVID, 16(50, 1.3) Number Long-term Symptoms after COVID Nonee 2.1 (SD 1.3)	Chronic Obstructive Pulmonary Disease	77 (3.9%)
Rheumatological Disease 31 (1.6%) Other (Cancer, Kidney Disease) 332 (16.9%) Stay at the hospital, mean (SD), days 11.3 (11.4) Intensive Care Unit (ICU) admission 130 (6.6%) / 1.4 Yes/No, n (%) 130 (6.6%) / 1.4 Number of long-term symptoms after COVID, n (%) 367 (18.7%) None 367 (18.7%) One 436 (22.1%) Two 488 (24.8%) 3 or more 436 (22.1%) Dug-Term symptoms after COVID, n (%) 488 (24.8%) Partice 1,206 (61.3%) Dyspnoea 459 (23.3%) Loss memory 341 (17.3%) Skin Rashes 236 (12.0%) Brain fog 140 (7.1%) Castrointestinal Disorders 140 (7.1%) Altention Disorders 133 (6.7%) Ocular/Vision Disorders 36 (2.5%) Disarin fog 80 (4%) Ageusia 53 (2.7%) Throat Pain 53 (2.5%) Disorders 39 (2%) Covidar/Vision Disorders 39 (2%) Disorders 39 (2%)	Stroke	38 (2.0%)
Other (Cancer, Kidney Disease) 332 (16.9%) Stay at the hospital, mean (SD), days 11.3 (11.4) Intensive Care Unit (ICU) admission 330 (6.6%) / 1.4 Yes/No, n (%) 300 (6.6%) / 1.4 Number of long-term symptoms after COVID, n (%) 367 (18.7%) None 367 (18.7%) One 436 (22.1%) Two 438 (24.8%) 3 or more 679 (34.4%) Long-term symptoms after COVID, n (%) 1206 (61.3%) Long-term symptoms after COVID, n (%) 1206 (61.3%) Long-term symptoms after COVID, n (%) 1206 (61.3%) Dyspnoea 459 (23.3%) Loss memory 341 (17.3%) Skin Rashes 236 (10.0%) Brain fog 189 (95.5%) Attention Disorders 140 (7.1%) Gastrointestinal Disorders 30 (4%) Angeusia 30 (4%) Ageusia 313 (6.7%) Ocular/Vision Disorders 30 (2.5%) Jarnetea 40 (2.5%) Voice Problems 30 (2.5%) Diarrhea 49 (2.5%)	Rheumatological Disease	
Stay at the hospital, mean (SD), days 11.3 (11.4) Intensive Care Unit (ICU) admission (30, 66.8) / 1.1, (93.4%) Ves/No, n (%) (30, 66.8) / 1.1, (93.4%) Number of long-term symptoms after COVID, n (%) (36.7, (18.7%) None 367 (18.7%) One 436 (22.1%) Two 438 (24.8%) 3 or more 679 (34.4%) Long-Term symptoms after COVID, n (%) 12.066 (61.3%) Patigue 1,206 (61.3%) Josp more 12.06 (61.3%) Loss memory 341 (17.3%) Skin Rashes 236 (12.0%) Brain fog 140 (7.1%) Palpitations 140 (7.1%) Coular/Vision Disorders 140 (7.1%) Qualizioni Lison ders 133 (6.7%) Ocular/Vision Disorders 133 (5.7%) Ocular/Vision Disorders 133 (5.7%) Voice Problems 39 (2.5%) No Dyspnoc	Other (Cancer, Kidney Disease)	
Intensive Care Unit (ICU) admission 130 (6.6%) / 1.4 (93.4%) Yes/No, n (%) 130 (6.6%) / 1.4 (93.4%) Number of long-term symptoms after COVID, n (%) (93.4%) None 367 (18.7%) One 436 (22.1%) Two 488 (24.8%) 3 or more 488 (24.8%) Long-Term symptoms after COVID, n (%) 7 Fatigue 1,206 (61.3%) Joyspnoea 459 (23.3%) Loss memory 341 (17.3%) Skin Rashes 236 (12.0%) Brain fog 189 (95.5%) Attention Disorders 140 (7.1%) Palpitations 140 (7.1%) Gastrointestinal Disorders 133 (6.7%) Ocular/Vision Disorders 133 (6.7%) Ocular/Vision Disorders 133 (6.7%) Ocular/Vision Disorders 16 (5.9%) Anosmia 80 (4%) Ageusia 53 (2.7%) Throat Pain 50 (2.55%) Diarrhea 49 (2.5%) Voice Problems 50 (2.55%) Diarrhea 50 (2.5%) <td< td=""><td></td><td></td></td<>		
Yes/No, n (%) 130 (6.6%) / 1.4 Number of long-term symptoms after COVID, n (%) 367 (18.7%) None 367 (18.7%) One 436 (22.1%) Two 436 (22.1%) Two 438 (24.8%) 3 or more 679 (34.4%) Long-Term symptoms after COVID, n (%) 12.06 (61.3%) Pyspnoea 12.06 (61.3%) Dyspnoea 459 (23.3%) Loss memory 341 (17.3%) Skin Rashes 236 (12.0%) Brain fog 140 (7.1%) Attention Disorders 140 (7.1%) Gastrointestinal Disorders 140 (7.1%) Ageusia 133 (6.7%) Ocular/Vision Disorders 113 (6.5%) Ageusia 53 (2.7%) Throat Pain 50 (2.55%) Diarrhea 49 (2.5%) Voice Problems 39 (2%) COVID-19 Onset Symptom at Hospital Admission Number Toyspnoea (n=620) 2.1 (SD 1.3) No Dyspnoea (n=1.349) 8.1 (SD 1.4)		11.5 (11.1)
Number of long-term symptoms after COVID, n (%) (93.4%) None 367 (18.7%) One 436 (22.1%) Two 488 (24.8%) 3 or more 679 (34.4%) Long-Term symptoms after COVID, n (%) 1,206 (61.3%) Patigue 1,206 (61.3%) Dyspnoea 459 (23.3%) Loss memory 341 (17.3%) Skin Rashes 236 (12.0%) Brain fog 189 (9.5%) Attention Disorders 140 (7.1%) Palpitations 140 (7.1%) Palpitations 140 (7.1%) Quality/Vision Disorders 116 (5.9%) Anosmia 80 (4%) Ageusia 53 (2.7%) Throat Pain 50 (2.55%) Diarrhea 49 (2.5%) Voice Problems 39 (2%) COVID-19 Onset Symptom at Hospital Admission Number Long-term Symptoms after COVID Typspnoea (n=620) 21 (5D 1.3) No Dyspnoea (n=1,349) 18 (5D 1.4)		120 (6 6%) / 1 820
Number of long-term symptoms after COVID, n (%) 367 (18.7%) None 367 (18.7%) One 436 (22.1%) Two 488 (24.8%) 3 or more 679 (34.4%) Long-Term symptoms after COVID, n (%) 1206 (61.3%) Paysnoea 459 (23.3%) Dyspnoea 459 (23.3%) Dyspnoea 459 (23.3%) Skin Rashes 236 (12.0%) Brain fog 341 (17.3%) Attention Disorders 140 (7.1%) Pajtitions 140 (7.1%) Gastrointestinal Disorders 140 (7.1%) Collar/Vision Disorders 133 (6.7%) Ocular/Vision Disorders 116 (5.9%) Anosmia 80 (4%) Ageusia 50 (2.5%) Diarrhea 49 (2.5%) Voice Problems 39 (2%) COVID-19 Onset Symptom at Hospital Admission Number Long-term Symptoms after Outgo-terolems 20 (2.5%) Diarrhea 49 (2.5%) Voice Problems 39 (2%) Dyspnoea (n=620)	res/no, n (%)	
None 367 (18.7%) One 436 (22.1%) Two 488 (24.8%) 3 or more 679 (34.4%) Long-Term symptoms after COVID, n (%) 1.206 (61.3%) Fatigue 1.206 (61.3%) Dyspnoea 459 (23.3%) Loss memory 341 (17.3%) Skin Rashes 236 (12.0%) Brain fog 189 (9.5%) Attention Disorders 140 (7.1%) Gastrointestinal Disorders 140 (7.1%) Gastrointestinal Disorders 133 (6.7%) Ocular/Vision Disorders 139 (2.5%) Voice Problems 50 (2.55%) Diarrhea 49 (2.5%) Voice Problems 39 (2%) CovID-19 Onset Symptom at Hospital Admission Number Long-term Symptoma (n=620)	Number of long term sumptoms after COVID_n (%)	(95.4%)
One 436 (22.1%) Two 436 (22.1%) Two 488 (24.8%) 3 or more 679 (34.4%) Long-Term symptoms after COVID, n (%) 1,206 (61.3%) Patigue 1,206 (61.3%) Dyspnoea 459 (23.3%) Loss memory 341 (17.3%) Skin Rashes 236 (12.0%) Brain fog 140 (7.1%) Attention Disorders 140 (7.1%) Palpitations 140 (7.1%) Gastrointestinal Disorders 133 (6.7%) Ocular/Vision Disorders 50 (2.55%) Diarrhea 49 (2.5%) Voice Problems 39 (2%) COVID-19 Onset Symptom at Hospital Admission Number Long-term Symptoms after Opspnoea (n=620) 2.1 (SD 1.3) No Dyspnoea (n=1,349) 1.8 (SD 1.4)		267 (10 7%)
Two 488 (24.8%) 3 or more 679 (34.4%) Log-Term symptoms after COVID, n (%) 1,206 (61.3%) Fatigue 1,206 (61.3%) Dyspnoea 459 (23.3%) Loss memory 341 (17.3%) Skin Rashes 236 (12.0%) Brain fog 189 (9.5%) Attention Disorders 140 (7.1%) Palpitations 140 (7.1%) Gastrointestinal Disorders 133 (6.7%) Ocular/Vision Disorders 116 (5.9%) Anosmia 80 (4%) Ageusia 53 (2.7%) Diarrhea 49 (2.5%) Voice Problems 59 (23.5%) Oct/IP-19 Onset Symptom at Hospital Admission Number Long-term Symptoms after COVID-19 Onset (n=620) No Dyspnoea (n=620) 2.1 (SD 1.3) No Dyspnoea (n=1,349) 1.8 (SD 1.4)		
3 or more 679 (34.4%) Long-Term symptoms after COVID, n (%) 1,206 (61.3%) Fatigue 1,206 (61.3%) Dyspnoea 459 (23.3%) Loss memory 341 (17.3%) Skin Rashes 236 (12.0%) Brain fog 189 (9.5%) Attention Disorders 140 (7.1%) Palpitations 140 (7.1%) Gastrointestinal Disorders 133 (6.7%) Ocular/Vision Disorders 116 (5.9%) Anosmia 80 (4%) Ageusia 53 (2.7%) Diarrhea 99 (2.5%) Voice Problems 99 (2.5%) COVID-19 Onset Symptom at Hospital Admission Number Long-term Symptoms after Ovylpspnoea (n=620) 2.1 (SD 1.3) No Dyspnoea (n=1,349) 18 (SD 1.4)		
Long-Term symptoms after COVID, n (%) 1,206 (61.3%) Fatigue 1,206 (61.3%) Dyspnoea 459 (23.3%) Loss memory 341 (17.3%) Skin Rashes 236 (12.0%) Brain fog 189 (9.5%) Attention Disorders 140 (7.1%) Palpitations 140 (7.1%) Gastrointestinal Disorders 133 (6.7%) Ocular/Vision Disorders 116 (5.9%) Anosmia 80 (4%) Ageusia 50 (2.55%) Diarrhea 49 (2.5%) Voice Problems 39 (2%) COVID-19 Onset Symptom at Hospital Admission Number Long-term Symptoms after Obyspnoea (n=620) 2.1 (SD 1.3) No Dyspnoea (n=1,349) 1.8 (SD 1.4)		
Fatigue 1,206 (61.3%) Dyspnoea 459 (23.3%) Loss memory 341 (17.3%) Skin Rashes 236 (12.0%) Brain fog 189 (9.5%) Attention Disorders 140 (7.1%) Palpitations 140 (7.1%) Gastrointestinal Disorders 133 (6.7%) Ocular/Vision Disorders 116 (5.9%) Anosmia 80 (4%) Ageusia 50 (2.55%) Diarrhea 49 (2.5%) Voice Problems 39 (2%) COVID-19 Onset Symptom at Hospital Admission Number Long-term Symptoms after Dyspnoea (n=620) 2.1 (SD 1.3) No Dyspnoea (n=1,349) 1.8 (SD 1.4)	3 or more	679 (34.4%)
Dyspnoea 459 (23.3%) Loss memory 341 (17.3%) Skin Rashes 236 (12.0%) Brain fog 189 (9.5%) Attention Disorders 140 (7.1%) Palpitations 140 (7.1%) Gastrointestinal Disorders 140 (7.1%) Ocular/Vision Disorders 133 (6.7%) Ocular/Vision Disorders 116 (5.9%) Anosmia 80 (4%) Ageusia 53 (2.7%) Throat Pain 50 (2.55%) Diarrhea 49 (2.5%) Voice Problems 39 (2%) COVID-19 Onset Symptom at Hospital Admission Number Long-term Symptoms after Opspnoea (n=620) 2.1 (SD 1.3) No Dyspnoea (n=1,349) 1.8 (SD 1.4)	.ong-Term symptoms after COVID, n (%)	
Loss memory 341 (17.3%) Skin Rashes 236 (12.0%) Brain fog 189 (9.5%) Attention Disorders 140 (7.1%) Palpitations 140 (7.1%) Gastrointestinal Disorders 133 (6.7%) Ocular/Vision Disorders 133 (6.7%) Ocular/Vision Disorders 116 (5.9%) Anosmia 80 (4%) Ageusia 53 (2.7%) Throat Pain 50 (2.55%) Diarrhea 49 (2.5%) Voice Problems 39 (2%) COVID-19 Onset Symptom at Hospital Admission Number Long-term Symptoms after Opspnoea (n=620) 2.1 (SD 1.3) No Dyspnoea (n=1,349) 1.8 (SD 1.4)	Fatigue	1,206 (61.3%)
Skin Rashes 236 (12.0%) Brain fog 189 (9.5%) Attention Disorders 140 (7.1%) Palpitations 140 (7.1%) Gastrointestinal Disorders 133 (6.7%) Ocular/Vision Disorders 133 (6.7%) Ocular/Vision Disorders 116 (5.9%) Anosmia 80 (4%) Ageusia 53 (2.7%) Throat Pain 50 (2.55%) Diarrhea 49 (2.5%) Voice Problems 39 (2%) COVID-19 Onset Symptom at Hospital Admission Number Long-term Symptoms after Dyspnoea (n=620) 2.1 (SD 1.3) No Dyspnoea (n=1,349) 1.8 (SD 1.4)	Dyspnoea	459 (23.3%)
Brain fog 189 (9.5%) Attention Disorders 140 (7.1%) Palpitations 140 (7.1%) Gastrointestinal Disorders 133 (6.7%) Ocular/Vision Disorders 133 (6.7%) Anosmia 80 (4%) Ageusia 53 (2.7%) Throat Pain 50 (2.55%) Diarrhea 49 (2.5%) Voice Problems 39 (2%) COVID-19 Onset Symptom at Hospital Admission Number Long-term Symptomea (n=620) 2.1 (SD 1.3) No Dyspnoea (n=1,349) 1.8 (SD 1.4)	Loss memory	341 (17.3%)
Brain fog 189 (9.5%) Attention Disorders 140 (7.1%) Palpitations 140 (7.1%) Gastrointestinal Disorders 133 (6.7%) Ocular/Vision Disorders 116 (5.9%) Anosmia 80 (4%) Ageusia 53 (2.7%) Throat Pain 50 (2.55%) Diarrhea 49 (2.5%) Voice Problems 39 (2%) COVID-19 Onset Symptom at Hospital Admission Number Long-term Symptoma functional function functional functional functional functional functional	skin Rashes	236 (12.0%)
Attention Disorders 140 (7.1%) Palpitations 140 (7.1%) Gastrointestinal Disorders 133 (6.7%) Ocular/Vision Disorders 116 (5.9%) Anosmia 80 (4%) Ageusia 53 (2.7%) Throat Pain 50 (2.55%) Diarrhea 49 (2.5%) Voice Problems 39 (2%) COVID-19 Onset Symptom at Hospital Admission Number Long-term Symptoms after Dyspnoea (n=620) 2.1 (SD 1.3) No Dyspnoea (n=1,349) 1.8 (SD 1.4)	Brain fog	
Palpitations 140 (7.1%) Gastrointestinal Disorders 133 (6.7%) Ocular/Vision Disorders 116 (5.9%) Anosmia 80 (4%) Ageusia 53 (2.7%) Diarrhea 50 (2.55%) Voice Problems 39 (2%) COVID-19 Onset Symptom at Hospital Admission Number Long-term Symptoms after Dyspnoea (n=620) 2.1 (SD 1.3) No Dyspnoea (n=1,349) 1.8 (SD 1.4)		, ,
Gastrointestinal Disorders 133 (6.7%) Ocular/Vision Disorders 116 (5.9%) Anosmia 80 (4%) Ageusia 53 (2.7%) Throat Pain 50 (2.55%) Diarrhea 49 (2.5%) Voice Problems 39 (2%) COVID-19 Onset Symptom at Hospital Admission Number Long-term Symptoms after Output COVID Dyspnoea (n=620) 2.1 (SD 1.3) No Dyspnoea (n=1,349) 1.8 (SD 1.4)		
Ocular/Vision Disorders 116 (5.9%) Anosmia 80 (4%) Ageusia 53 (2.7%) Throat Pain 50 (2.55%) Diarrhea 49 (2.5%) Voice Problems 39 (2%) COVID-19 Onset Symptom at Hospital Admission Number Long-term Symptoms after Opspnoea (n=620) 2.1 (SD 1.3) No Dyspnoea (n=1,349) 1.8 (SD 1.4)	1	
Anosmia 80 (4%) Ageusia 53 (2.7%) Throat Pain 50 (2.55%) Diarrhea 49 (2.5%) Voice Problems 39 (2%) COVID-19 Onset Symptom at Hospital Admission Number Long-term Supprove (n=620) * Dyspnoea (n=620) 2.1 (SD 1.3) No Dyspnoea (n=1,349) 1.8 (SD 1.4)		, ,
Ageusia 53 (2.7%) Throat Pain 50 (2.55%) Diarrhea 49 (2.5%) Voice Problems 39 (2%) COVID-19 Onset Symptom at Hospital Admission Number Long-term * Dyspnoea (n=620) 2.1 (SD 1.3) No Dyspnoea (n=1,349) 1.8 (SD 1.4)		
Throat Pain 50 (2.55%) Diarrhea 49 (2.5%) Voice Problems 39 (2%) COVID-19 Onset Symptom at Hospital Admission Number Long-term Symptoms after Symptoms after COVID Symptoms after COVID * Dyspnoea (n=620) 2.1 (SD 1.3) No Dyspnoea (n=1,349) 1.8 (SD 1.4)		
Diarrhea 49 (2.5%) Voice Problems 39 (2%) COVID-19 Onset Symptom at Hospital Admission Number Long-term Symptoms after COVID * Dyspnoea (n=620) 2.1 (SD 1.3) No Dyspnoea (n=1,349) 1.8 (SD 1.4)		
Voice Problems 39 (2%) COVID-19 Onset Symptom at Hospital Admission Number Long-term Symptoms after Symptoms (n=620) 2.1 (SD 1.3) No Dyspnoea (n=1,349) 1.8 (SD 1.4)		
COVID-19 Onset Symptom at Hospital AdmissionNumber Long-term Symptoms after COVID*Dyspnoea (n=620)2.1 (SD 1.3)No Dyspnoea (n=1,349)1.8 (SD 1.4)		
Long-term Symptoms after *Dyspnoea (n=620) No Dyspnoea (n=1,349) 1.8 (SD 1.4)	/oice Problems	39 (2%)
Symptoms after *Dyspnoea (n=620) 2.1 (SD 1.3) No Dyspnoea (n=1,349) 1.8 (SD 1.4)	COVID-19 Onset Symptom at Hospital Admission	Number
COVID *Dyspnoea (n=620) 2.1 (SD 1.3) No Dyspnoea (n=1,349) 1.8 (SD 1.4)		Long-term
*Dyspnoea (n=620) 2.1 (SD 1.3) No Dyspnoea (n=1,349) 1.8 (SD 1.4)		Symptoms after
*Dyspnoea (n=620) 2.1 (SD 1.3) No Dyspnoea (n=1,349) 1.8 (SD 1.4)		• •
No Dyspnoea (n=1,349) 1.8 (SD 1.4)	Dyspace (n=620)	
11eductie (11=552) 2.2 (5D 1.4)		
No Headacha (n. 1637) 19 (6D 12)		
No Headache (n=1,637) 1.8 (SD 1.3)		
*Diarrhea (n=210) 2.25 (SD 1.4)		
No Diarrhea (n=1,759) 1.8 (SD 1.4)		
*Throat Pain (n=102) 2.35 (SD 1.4)		. ,
No Throat Pain (n=1,867) 1.85 (SD 1.4)	No Throat Pain (n=1,867)	1.85 (SD 1.4)
*Vomiting (n=55) 2.5 (SD 1.4)	Vomiting (n=55)	2.5 (SD 1.4)
No Vomiting (n=1,914) 1.85 (SD 1.3)	No Vomiting (n=1,914)	1.85 (SD 1.3)

* Significant association in the multivariate analysis

Acknowledgments

We want to acknowledge all participants with COVID-19 of this study for their attention

Role of the Funding Source

. The LONG-COVID-EXP-CM is supported by a grant of Comunidad de Madrid y la Unión Europea, a través del Fondo Europeo de Desarrollo Regional (FEDER), Recursos REACT-UE del Programa Operativo de Madrid 2014-2020, financiado como parte de la respuesta de la Unión a la pandemia de COVID-19. The sponsor had no role in the design, collection, management, analysis, or interpretation of the data, draft, review, or approval of the manuscript, or its content. The authors were responsible for the decision to submit the manuscript for publication, and the sponsor did not participate in this decision.

References

- Fernández-de-las-Peñas C, Palacios-Ceña D, Gómez-Mayordomo V, Florencio LL, Cuadrado ML, Plaza-Manzano G, Navarro-Santana M. Prevalence of Post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: A systematic review and meta-analysis. Eur J Int Med 2021;92:55–70.
- Iqbal FM, Lam K, Sounderajah V, Clarke JM, Ashrafian H, Darzi A. Characteristics and predictors of acute and chronic post-COVID syndrome: A systematic review and meta-analysis. EClinicalMedicine 2021;36.
- Jacobs L, Koyanagi AI, Smith L, Tanislav C, Konrad M, van der Beck S, Kostev K. Prevalence of and factors associated with long-term COVID-19 sick leave in working-age patients followed in general practices in Germany. Int J Infectious Diseases 2021. doi:10.1016/j.ijid.2021.06.063.
- Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis 2021. doi:10.1080/23744235.2021.192439.